Souied Eric H, Reid Silvia N M, Piri Natik I, Lerner Leonid E, Nusinowitz Steven, Farber Debora B
Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Exp Eye Res. 2008 Sep;87(3):168-75. doi: 10.1016/j.exer.2008.04.009. Epub 2008 Apr 29.
Despite extensive research on many of the genes responsible for inherited retinal degenerations leading to blindness, no effective treatment is currently available for patients affected with these diseases. Among the therapeutic approaches tested on animal models of human retinal degeneration, gene therapy using different types of viral vectors as delivery agents has yielded promising results. We report here our results on a non-invasive, non-viral delivery approach using transscleral iontophoresis for transfer of plasmid DNA into mouse retina. Proof of principle experiments were carried out using plasmid containing GFP cDNA to demonstrate expression of the transferred gene in the retina after single applications of iontophoresis. Various parameters for multiple applications of iontophoresis were optimized to sustain GFP gene expression in mouse photoreceptors. Subsequently, repeated iontophoresis of plasmid containing normal cGMP-phosphodiesterase beta-subunit (beta-PDE) cDNA was performed in the rd1 mouse, an animal model of autosomal recessive retinitis pigmentosa caused by a mutant beta-PDE gene. In normal mice, transscleral iontophoresis of the GFP plasmid provided a significant increase in fluorescence of the retina in the treated versus non-treated eyes. In rd1 mice, repeated iontophoresis of beta-PDE cDNA plasmid partially rescued photoreceptors morphologically, as observed by microscopy, and functionally, as recorded on ERG measurements, without adverse effects. Therefore, transscleral iontophoresis of plasmid DNA containing therapeutic genes may be an efficient, safe and non-invasive method for the treatment of retinal degenerations.
尽管对许多导致失明的遗传性视网膜变性相关基因进行了广泛研究,但目前对于受这些疾病影响的患者尚无有效的治疗方法。在人类视网膜变性动物模型上测试的治疗方法中,使用不同类型病毒载体作为递送剂的基因疗法已取得了有前景的结果。我们在此报告使用经巩膜离子电渗疗法将质粒DNA导入小鼠视网膜的非侵入性、非病毒递送方法的结果。使用含有绿色荧光蛋白(GFP)互补DNA(cDNA)的质粒进行原理验证实验,以证明单次离子电渗疗法后视网膜中转移基因的表达。对多次离子电渗疗法的各种参数进行了优化,以维持小鼠光感受器中GFP基因的表达。随后,在rd1小鼠(一种由突变型β - 磷酸二酯酶基因引起的常染色体隐性视网膜色素变性动物模型)中对含有正常环鸟苷酸磷酸二酯酶β亚基(β - PDE)cDNA的质粒进行重复离子电渗疗法。在正常小鼠中,经巩膜离子电渗疗法导入GFP质粒后,与未治疗的眼睛相比,治疗眼睛的视网膜荧光显著增加。在rd1小鼠中,通过显微镜观察,β - PDE cDNA质粒的重复离子电渗疗法在形态学上部分挽救了光感受器,并且通过视网膜电图(ERG)测量记录,在功能上也有挽救作用,且无不良影响。因此,经巩膜离子电渗疗法导入含治疗基因的质粒DNA可能是一种治疗视网膜变性的有效、安全且非侵入性的方法。